OSI-027 (formerly known as ASP4786; AEVI006; CERC006) is a novel, potent, selective, orally bioavailable and ATP-competitive dual inhibitor of mTORC1 (mammalian target of rapamycin 1) and mTORC2 with potential anticancer activity.

Zotarolimus (also known as ABT-578; A 179578), a tetrazole-based and semi-synthetic analog of rapamycin, is a highly potent immunosuppressant with the potential to be used for preventing coronary artery restenosis.

(+)-Usniacin, [(+)-Usnic acid] is a natually occuring compound isolated from lichens, which binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity.

WYE-687 is a novel, potent, ATP-competitive and selective inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity.

L-LEUCINE-13C6, is a D-Leucine.

Salidroside (Rhodioloside), a naturally occuring phenylpropanoid glycoside isolated from Rhodiola rosea, has been reported to have a broad spectrum of pharmacological properties such as anticancer, antidepressant and anxiolytic effects.

Palomid 529 (also called P529, SG00-529), developed by Paloma Pharmaceuticals, is a novel and potent inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity.

Tacrolimus (FK506, Fujimycin, FR-900506, Prograf), a natural macrocyclic lactone isolated from the fungus Streptomyces tsukubaensis, is a potent immunosuppressive agent used with other medications to prevent rejection of organ (kidney, heart, liver) transplant.

MHY1485 (MHY-1485) is a novel, potent and cell-permeable activator of mTOR (mammalian target of rapamycin) and an inhibitor of autophagy that suppress the fusion between autophagosomes and lysosomes.

Ridaforolimus (also known as deforolimus, AP-23573; MK-8669) is a novel, potent, investigational and selective mTOR inhibitor with significant antitumor effects.